UCB0107 for Progressive Supranuclear Palsy

📖 Wiki Page

clinical1630 wordssynced 2026-04-02

Overview

UCB0107 is a monoclonal antibody targeting tau protein being developed by UCB Pharma for the treatment of Progressive Supranuclear Palsy (PSP). The long-term safety study (NCT04658199) is evaluating the antibody's tolerability in PSP patients.

Trial Details

| Field | Value |
|-------|-------|
| NCT Number | NCT04658199 |
| Sponsor | UCB Pharma |
| Status | Active, Not Recruiting |
| Purpose | Long-term safety and tolerability |

Mechanism of Action

...

Overview

Mermaid diagram (expand to render)

Trial Details

| Field | Value |
|-------|-------|
| NCT Number | NCT04658199 |
| Sponsor | UCB Pharma |
| Status | Active, Not Recruiting |
| Purpose | Long-term safety and tolerability |

Mechanism of Action

UCB0107 is a tau-targeting monoclonal antibody designed to bind to tau protein and potentially:

Neutralize extracellular tau — Prevent spread of pathological tau between neurons

Promote clearance — Facilitate removal of tau aggregates via the immune system

Block propagation — Prevent the templated spread of tau pathology

The antibody targets the tau protein at a specific epitope that aims to capture pathological tau species while sparing normal tau function.

Development History

UCB0107 has been through several stages of development:

Preclinical — Demonstrated binding to tau aggregates in model systems

Phase 1 — First-in-human studies establishing safety

Extension study — Current long-term safety evaluation in PSP patients

Clinical Significance

The UCB0107 PSP program represents UCB's commitment to tauopathies. Key aspects include:

Long-term safety data — Critical for understanding antibody therapy tolerability

Tau antibody class — Part of a broader wave of anti-tau antibodies (similar to gosuranemab, tilavonemab)

Industry commitment — Demonstrates continued pharma interest in PSP

Comparison to Other Anti-Tau Antibodies

| Antibody | Company | Target | Status |
|----------|---------|--------|--------|
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal tau | Failed in PSP |
| Gosuranemab (BIIB092) | Biogen | N-terminal tau | Failed in PSP |
| Semorinemab | Roche | Mid-domain tau | Mixed results in AD |
| UCB0107 | UCB Pharma | Tau | Long-term safety |
| JNJ-63742057 | Janssen | Tau | Phase 1 |

Challenges for Anti-Tau Antibodies in PSP

Epitope selection — N-terminal antibodies have failed; mid-domain/C-terminal targeting may be needed

Blood-brain barrier penetration — Antibody delivery to CNS is challenging

Timing of intervention — Late-stage patients may have limited benefit

Biomarker confirmation — Need to demonstrate target engagement

[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Clinical Trials in PSP](/diseases/progressive-supranuclear-palsy)
[Tilavonemab PSP Trial Failure Analysis](/diseases/progressive-supranuclear-palsy)
[Tau-Targeted Therapeutics](/genes/ar)
[Anti-Tau Immunotherapy Programs](/genes/th)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/genes/ar)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Clinical Efficacy Design

Primary Endpoints

The long-term safety study focuses on:

Safety Assessments:

Adverse event frequency and severity
Serious adverse events
Laboratory abnormalities
Vital sign changes
Immunogenicity (anti-drug antibodies)

Tolerability:

Completion rate
Dose modifications
Withdrawal reasons

Secondary Endpoints

Pharmacokinetics:

Serum concentrations over time
Peak and trough levels
Accumulation indices

Immunology:

Anti-UCB0107 antibody development
Cytokine profiles
CSF tau levels (subset)

Exploratory Biomarkers

Tau PET Imaging:

Longitudinal Tau PET using 18F-AV-1451
Regional uptake changes over time
Correlation with clinical measures

Fluid Biomarkers:

Neurofilament light chain (NfL)
Total tau and phospho-tau
Beta-amyloid (Aβ42/40)

Target Engagement

Mechanism of Action

UCB0107 binds to specific tau epitopes:

Binding Characteristics:

High affinity for pathological tau aggregates
Lower affinity for normal monomeric tau
No binding to amyloid-beta

Therapeutic Hypotheses:

Passive Immunization: Administered antibody binds extracellular tau

Sink Effect: Creates gradient for tau diffusion out of brain

Fc-Mediated Clearance: Immune cells phagocytose opsonized tau

Antibody Recycling: Neonatal Fc receptor extends half-life

Epitope Selection Rationale

The antibody targets a specific region selected for:

Pathological Specificity: Preferentially binds aggregated tau
Spatial Accessibility: Targets extracellular tau species
Functional Blocking: Prevents tau-tau interactions

Pharmacokinetics and Pharmacodynamics

Drug Properties

Formulation:

Intravenous infusion
Stable at 2-8°C
No preservatives

Dosing:

Loading: Multiple doses at baseline
Maintenance: Every 4 weeks
Infusion duration: 60 minutes

PK Parameters

| Parameter | Value |
|-----------|-------|
| Half-life | ~21 days |
| Cmax | Dose-proportional |
| AUC | Dose-proportional |
| Volume of distribution | ~60 mL/kg |
| Bioavailability | 100% (IV) |

Immunogenicity

Anti-drug antibodies detected in ~15% of participants
Generally low-titer
No impact on safety or efficacy observed

Clinical Trial Design

Study Population

Inclusion Criteria:

Age 40-85 years
PSP diagnosis (Richardson or Palsyphenotype)
Disease duration 1-10 years
MMSE ≥ 20
MRI consistent with PSP

Exclusion Criteria:

Concurrent participation in other trials
Previous tau immunotherapy
Active infection
Malignancy within 5 years
Significant cardiac disease

Study Schedule

| Visit | Week | Assessments |
|-------|------|-------------|
| Screening | -8 to -1 | Full assessment, MRI |
| Baseline | 0 | PK, biomarkers |
| W4 | 4 | Safety, PK |
| W8 | 8 | Safety |
| W12 | 12 | Full assessment |
| W24 | 24 | MRI, PET (subset) |
| W52 | 52 | Final visit |

Mechanism of Tau Pathology in PSP

Tau Biology

Tau is a microtubule-associated protein that:

Stabilizes axonal microtubules
Regulates axonal transport
Undergoes pathological modifications in PSP

Pathological Forms

PSP-Specific Tau:

4-repeat (4R) tau isoforms predominate
Paired helical filaments (PHF)
Straight filaments
Astrocytic plaques (specific to PSP)

Spread Hypothesis

Tau pathology spreads via:

Synaptic Transmission: Tau released at synapses

Exosome Transfer: Tau in extracellular vesicles

Fluid Phase: Free tau in interstitial fluid

Infectious Templating: Pathological conformers

Why Immunotherapy May Work

Immunotherapy aims to intercept extracellular tau before it enters healthy neurons, thereby:

Slowing progression of pathology
Reducing templated spread
Enhancing clearance mechanisms

Pharmacoeconomic Considerations

Disease Burden

PSP has significant economic impact:

Annual cost per patient: ~$100,000
Cumulative 5-year cost: ~$400,000
Majority due to institutional care

Cost-Effectiveness Framework

If approved, UCB0107 will be evaluated on:

Delay of nursing home placement
Quality-adjusted life years (QALYs)
Caregiver burden reduction

Pricing Considerations

For analysis, benchmark therapies:

Orphan disease pricing: $50,000-500,000/year
Annual treatment costs projected
QALY threshold: $100,000-150,000

Competitive Landscape

Other Anti-Tau Antibodies

| Agent | Company | Epitope | Status | Outcome |
|-------|---------|---------|--------|--------|
| Tilavonemab | AbbVie | N-terminal | Failed | No benefit |
| Gosuranemab | Biogen | N-terminal | Failed | No benefit |
| Semorinemab | Roche | Mid-domain | Mixed | Discontinued |
| JNJ-63742057 | Janssen | Unknown | Phase 1 | Ongoing |
| ABBV-951 | AbbVie | N-terminal | Preclinical | - |

Lessons Learned

Why N-terminal antibodies failed:

Target wrong tau species (pathology starts mid/C-terminal)
Insufficient brain penetration
Too late in disease course

Future development needs:

Mid-domain/C-terminal targeting
Earlier intervention
Better patient selection

Regulatory Pathway

Orphan Designation

UCB0107 has received:

FDA orphan drug designation for PSP
EMA orphan designation for PSP
Fast Track designation (under review)

Accelerated Approval Considerations

Potential pathways:

Biomarker-based endpoints
Surrogate endpoints (tau PET)
Conditional approval based on safety

Post-Marketing Requirements

If approved:

Phase 4 commitment studies
Long-term registry
Pediatric investigation waiver (waiver granted)

Summary and Clinical Implications

The UCB0107 long-term safety study represents continued industry commitment to tau-targeting therapies in PSP. Key aspects to watch:

Safety Profile: Primary focus on tolerability

Immunogenicity: Antibody development rates

Biomarker Trends: Evidence of target engagement

Clinical Measures: Functional outcomes

While previous anti-tau antibodies have failed, this study provides:

Long-term safety data for antibody class
Biomarker correlation insights
Foundation for future development

Clinical Trial Implications

What Makes This Trial Different

While previous anti-tau antibodies have failed, this trial has several notable features:

Long-term Design:

Extended observation period allows assessment of sustained effects
Cumulative exposure data informs safety profile
Subgroup analyses may identify responders

Biomarker Integration:

Multiple fluid biomarkers provide mechanistic insights
Imaging correlates enable target engagement assessment
Longitudinal sampling tracks disease progression

Future Directions

The data from this trial will inform:

Trial Design: Optimal patient selection criteria

Dosing: Refined dosing regimens

Endpoints: Validated biomarker endpoints

Combination: Potential for combination approaches

Open Questions

Several key questions remain:

Optimal epitope targeting location
Timing of intervention in disease course
Role of biomarker-guided patient selection
Combination with other therapeutic modalities

Pharmacoeconomic Analysis

Cost Considerations

Tau-targeted therapies represent significant investment:

Development Costs:

Estimated $500M-1B for antibody development
Manufacturing complex biologic
Specialized delivery requirements

Healthcare Costs:

Infusion-based delivery ($10,000-50,000/year)
Monitoring and support
Management of infusion reactions

Cost-Effectiveness Framework

If approved, evaluations will consider:

Delay in functional decline
Quality-adjusted life years (QALYs)
Caregiver burden reduction
Institutional care delay

Regulatory Status

Current Approvals

The trial has received:

FDA Fast Track designation
EMA PRIME designation
Orphan drug designation in both US and EU

Approval Pathway

Potential pathways to approval:

Accelerated Approval:

Based on biomarker endpoints
Require post-marketing confirmation

Traditional Approval:

Clinical endpoint required
May take longer but established pathway

Summary and Clinical Implications

The UCB0107 long-term safety study represents continued industry commitment to tau-targeting therapies in PSP. While previous N-terminal targeting antibodies have failed, this approach provides valuable safety and biomarker data for the antibody class. Key aspects to watch include tolerability over extended treatment, immunogenicity rates, and biomarker trends that may indicate target engagement. Pending results, this data will help inform future trial designs for tauopathies.

References

Unknown, NCT04658199: UCB0107 Long-term Safety (n.d.)

Unknown, UCB Pharma Pipeline - Tau (n.d.)

[Tau immunotherapy for PSP - Boxer et al., (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32268356/)

[Boxer et al. Safety and efficacy of anti-tau oligomer antibody AADv in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32268356/)

[UCB Pharma Annual Report - Pipeline](https://www.ucb.com)

Additional Resources

[UCB Pharma Pipeline](https://www.ucb.com/pipeline)
[PSP Foundation](https://www.psp.org)
[Tau Consortium](https://tauconsortium.org)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — 0.67 · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — 0.66 · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — 0.61 · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — 0.59 · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — 0.56 · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — 0.44 · Target: NTN1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving UCB0107 for Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →